Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) study

Circulation

Volumn 100, Issue 7, 1999, Pages 717-722

  Cushman, Mary ^a,b   Legault, Claudine ^c   Barrett Connor, Elizabeth ^d   Stefanick, Marcia L ^e   Kessler, Craig ^f   Judd, Howard L ^g   Sakkinen, Pamela A ^b   Tracy, Russell P ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f GEORGETOWN UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Coagulation; Hormones; Inflammation; Risk factors; Women

Indexed keywords

BLOOD CLOTTING FACTOR 8A; C REACTIVE PROTEIN; CONJUGATED ESTROGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ESTROGEN; GESTAGEN; PLACEBO; PROGESTERONE; VON WILLEBRAND FACTOR;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESTROGEN THERAPY; FEMALE; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 0033578463     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.7.717     Document Type: Article

References (27)

1. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health. 1998;19:55-72.
2. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ. 1997;315:149-153.
3. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
4. Tracy RP. Atherosclerosis, thrombosis and inflammation: a problem of linkage. Fibrinolysis and Proteolysis. 1997;11(suppl 1):137-141.
5. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999:340:115-126.
6. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol. 1996;144:537-547.
7. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
8. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilhan EN, Kuller LH. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997;17:1121-1127.
9. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AMJ, Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1997;96:4219-4225.
10. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1997;96:1102-1108.
11. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. A prospective study of C-reactive protein and risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-733.
12. Meade TW. Hormone replacement therapy and haemostatic function. Thromb Haemost. 1997;78:765-769.
13. Cushman M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, Tracy RP. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol. 1999;19:893-899.
14. Cushman M, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, Polak JF, Savage PJ, Tracy RP. Correlates of fibrinogen and coagulation factors VII and VIII in the elderly: results from the Cardiovascular Health Study. Am J Epidemiol. 1996;143:665-676.
15. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M, for the Atherosclerosis Risk in Communities Study Investigators. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993;328:1069-1075.
16. Lip GYH, Blann AD, Jones AF, Beevers DG. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J. 1997;134:764-771.
17. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199-208.
18. Espeland MA, Marcovina SM, Miller V, Wood PD, Wasilauskis C, Sherwin R, Schrott H, Bush TL, for the PEPI Investigators. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation. 1998;97:979-986.
19. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem. 1997;43:52-58.
20. Greenberg CS, Hursting MJ, Macik BG, Ortel TL, Kane WH, Moore BM. Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2. Clin Chem. 1994;40:1962-1969.
21. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963-974.
22. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, Wu KK, for the ARIC Study Investigators. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost. 1993;70:380-385.
23. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ. 1996;312:1061-1065.
24. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer M, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88-92.
25. Smith CW. Potential significance of circulating E-selectin. Circulation. 1997;95:1986-1988.
26. Schmid E, Muller TH, Budzinski RM, Binder K, Pfizenmaier K. Signaling by E-selectin, and ICAM-1 induces endothelial tissue factor production via autocrine secretion of platelet-activating factor and tumor necrosis factor alpha. J Interferon Cytokine Res. 1995;15:819-825.
27. Cid MC, Kleinman HK, Grant DS, Schnaper HW, Fauci AS, Hoffman GS. Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule type 1, and vascular cell adhesion molecule type 1. J Clin Invest. 1994;93:17-25.